Vivoxid Ltd.

Research and development of biomaterials and tissue generations

Vivoxid was founded in 2001.

Vivoxid Quality System is certified by the Danish Medical Devices Certification (ISO 9001:2000 and ISO 13485:2003).

Research at Vivoxid is i.a. encouraged by the Turku University Biomaterials Research Project and Abo Akademi Biomaterials research that were established in 1986.

Tomi Numminem, M.Sc, President, CEO
Ilkka Kangasniemi, Ph.D., CSO

Tykistökatu 4 A
20520 Turku
Finland
Phone: +358-20-7622 266
Fax: +358-20-7622 262

Vivoxid focuses on the research and development of biomaterials based on five different technologies including bioactive glasses, sol-gel silicates, sol-gel titania for soft tissue attachment applications, biodegradable polymers, cellulose sponges for wound bed preparation indications and their composite materials.

Bioactive glass technologies, the central part of Vivoxid’s biomaterial research activity, aim at the indication areas of dental, othorhinolaryngology and orthopaedic applications as bone filling materials and by replacing damaged bony tissue.

Vivoxid’s CE-marked products AbMinCranio™granules and AbMinCranio™plates are indicated for sinus obliteration, orbital wall reconstruction and extending areas of indication.

The main indication areas of Sol-gel titania are e.g. skin and mucosa penetrating implants, stents, valves and catheders.

MetAlive™ surface modification for metal implants is based on sol-gel derived titania chemistry and forms an ideal surface for metallic implants with its bioactive, bone bonding but not dissolvable surface characteristics.

The cellulose technology as another area of research i.a. concentrates on the development of wound dressings for the treatment of chronic wounds and burns. The dressing consists of purified cellulose sponge with an open pore-to-pore construction that prefers the living of inflammatory cells and of bacteria. By removing the wound dressing the infectious potential is removed as well.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.